Autolus Therapeutics plc - ADR

NASDAQ:AUTL  
6.16
+0.11 (+1.82%)
Regulatory, Other Pre-Announcement

Autolus Therapeutics Says In Allcar19 Trial, 1 Additional Patient Was Dosed, Who Died Due To Infectious Complications Assessed As Unrelated To Auto1

Published: 12/07/2020 21:35 GMT
Autolus Therapeutics plc - ADR (AUTL) - Autolus Therapeutics Plc - in Allcar19 Trial, 1 Additional Patient Was Dosed, Who Died Due to Infectious Complications Assessed As Unrelated to Auto1.
Autolus Therapeutics Plc - for Allcar19 Trial, Now Expects to Report Final Phase 1 Data in 2022.
Autolus Therapeutics - Evaluating Development of Auto1 for Treatment of Primary Central Nervous System Lymphoma, With Potential Study Start in Q1 2021.
Autolus Therapeutics - in Allcar19 Trial, 3 Patients Who Had High Leukemia Burden Experienced Grade 3 Nt That Resolved Swiftly With Steroids.